Home › Idiopathic Pulmonary Fibrosis › Minnesota
Idiopathic Pulmonary Fibrosis clinical trials in Minnesota
3 studies for Idiopathic Pulmonary Fibrosis are looking for participants at sites in Minnesota.
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
- Mayo Clinic Rochester, Rochester
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Nov 13, 2026 · NCT07671911Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- University of Minnesota, Minneapolis
RecruitingObservational study
Ages 21 and older · All sexes · Updated Nov 12, 2026 · NCT01915511An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
- Mayo Clinic Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06951217From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.